Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Core Viewpoint - Tevogen Bio Holdings Inc. aims to clarify its financial position by addressing the accumulated deficit reported under U.S. GAAP, emphasizing the need for a more comprehensive understanding of its financial metrics through non-GAAP measures [1][2][3]. Financial Position - The company has raised a total of under $42 million since its inception up to June 30, 2025 [3]. - As of June 30, 2025, the GAAP financial statements show an accumulated deficit of $129 million, which includes non-cash expenses of approximately $88 million [3]. - After accounting for a cash balance and additional capital raised of over $8.8 million, the total stockholders' deficit is reported to be under $9.5 million [3]. Non-GAAP Metrics - Tevogen plans to provide a fully reconciled set of non-GAAP metrics following the filing of its Form 10-Q for Q3 2025 to give investors a clearer picture of its financial health [2]. - The company emphasizes the distinction between cash and non-cash components in its financial results to enhance investor understanding [3]. Capital Efficiency - The commentary from the CFO highlights the company's strong capital efficiency and low cash burn rate, which is crucial for its ongoing operations and future growth [3].